Dr. Khong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2946 E Banner Gateway Dr
Gilbert, AZ 85234Phone+1 480-256-6444
Education & Training
- National Cancer Institute, Surgery BranchPost-Doctoral Fellowship, 1999 - 2004
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
- Baylor College of MedicineResidency, Internal Medicine, 1994 - 1997
- Lewis Katz School of Medicine at Temple UniversityClass of 1994
Certifications & Licensure
- AZ State Medical License 2023 - 2026
- FL State Medical License 2017 - 2025
- UT State Medical License 2011 - 2018
- AL State Medical License 2004 - 2011
- VA State Medical License 1998 - 2004
Clinical Trials
- A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer Start of enrollment: 2008 Sep 01
- Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer Start of enrollment: 2008 Sep 01
- A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsAuthor Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.Hatem Soliman, Deanna Hogue, Hyo Han, Blaise Mooney, Ricardo Costa
Nature Medicine. 2023-12-01 - 33 citationsOncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.Hatem Soliman, Deanna Hogue, Hyo Han, Blaise Mooney, Ricardo Costa
Nature Medicine. 2023-02-01 - 203 citationsElacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Nega...Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero
Journal of Clinical Oncology. 2022-10-01
Press Mentions
- Woman Rings Chemotherapy Bell After Fighting Breast Cancer While PregnantApril 30th, 2019
- Utah Researchers Helping Test Newest Melanoma DrugsMay 21st, 2016
Professional Memberships
- Member
Other Languages
- Vietnamese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: